BioMarin 制药公司表示，该公司试验药物 BMN 111(vosoritide) 在一项中期研究中，能够改善最常见形式侏儒症儿童的生长状况。BioMarin 称，这款药物在软骨发育不全儿童中得...
BioMarin pharmaceutical company said, the company's test drug BMN 111 vosoritide in a mid stage study, can improve the most common form of dwarfism children's growth. BioMarin said the drug was not fully developed in children with cartilage...
